evipedia.ai
← Back

Pregnenolone for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: P5, PREG, 3β-hydroxypregn-5-en-20-one, pregn-5-en-3β-ol-20-one, Δ5-pregnenolone

Motivation

Pregnenolone is a hormone the body builds from cholesterol in the adrenal glands, the gonads and the brain. It sits at the head of the steroid pathway, which means every other steroid hormone the body makes is constructed from it. It also works in the brain in its own right, adjusting the balance between alertness and calm. Those two roles are why it draws attention from people trying to hold on to function as they age.

It was isolated in the 1930s and tested in the 1940s and 1950s as an oral treatment for joint disease and for work fatigue, then set aside when cortisone arrived and proved far more powerful. It returned to the United States retail market in the 1990s as a supplement, sold largely on the premise that the body’s own levels fall with age. Measurement studies disagree on whether that premise is true.

This review examines what controlled human research shows about pregnenolone, which claims rest only on laboratory or animal work, what harms have been documented, and how it is dosed, sourced and monitored.

Benefits - Risks - Protocol - Conclusion

A short list of high-level pieces that give a broad orientation to pregnenolone’s biology, its proposed clinical uses and the state of the research.

Note on priority sources: of the six prioritized platforms, only Life Extension carries content that discusses pregnenolone in substantial depth. Rhonda Patrick, Peter Attia and Lifespan.io have no qualifying material, and what Andrew Huberman and Chris Kresser carry are brief asides inside broader hormone episodes; those were not padded into the list.

Grokipedia

  • Pregnenolone

    A structured reference covering pregnenolone’s chemistry, biosynthesis, neurosteroid signaling at GABA-A and NMDA receptors, pharmacology and research history, useful for orientation before the trial evidence below.

Examine

No Examine article exists for pregnenolone. Examine’s supplement database covers dietary ingredients it has reviewed, and pregnenolone is not among them.

ConsumerLab

Systematic Reviews

Pooled analyses that include pregnenolone as a named agent, selected for relevance, the number of trials pooled and recency.

The claimed-effect side of the trade-off is represented by all five. The risk side is only partly represented: Cho et al. and Li et al. pool adverse events, but no systematic review or meta-analysis addresses pregnenolone’s hormonal safety — androgenic conversion, prostate effects, or use beyond twelve weeks in adults without a psychiatric diagnosis. That side of the literature is unrepresented.

Mechanism of Action

Pregnenolone is made inside mitochondria when the cholesterol side-chain cleavage enzyme (CYP11A1, which trims cholesterol into the first steroid) acts on cholesterol. This happens in the adrenal cortex, the gonads and, independently, in brain glial cells; circulating pregnenolone also crosses into the brain. From there the pathway forks: 3β-hydroxysteroid dehydrogenase converts it to progesterone, while CYP17A1 (the enzyme that opens the androgen branch) converts it toward DHEA (dehydroepiandrosterone, the main adrenal androgen precursor) and onward to testosterone and estrogens.

It is not only a precursor. Sulfotransferases produce pregnenolone sulfate, which strengthens signaling at NMDA receptors (glutamate receptors central to learning) and weakens it at GABA-A receptors (the brain’s main calming receptors) — a combination favoring arousal. Pregnenolone also opens TRPM3 ion channels (which admit calcium into sensory neurons) and binds microtubule-associated protein 2, promoting assembly of the internal scaffolding neurons use to grow. Downstream, allopregnanolone does the opposite at GABA-A receptors. Pregnenolone additionally acts as a signaling-specific brake on the CB1 receptor (the brain receptor cannabis acts on).

Two mechanistic accounts compete: that oral pregnenolone works purely as a reservoir feeding active metabolites, or that it and its sulfate act directly. Trial data support each in part.

Pharmacologically it is fat-soluble, orally absorbed, unselective — it feeds every steroid branch — and cleared by sulfation (SULT2A1, which attaches a sulfate group) and the enzymes above. No formal human half-life has been published, though 300–500 mg split into two daily doses keeps plasma levels elevated eight hours past each dose.

Historical Context & Evolution

Pregnenolone was isolated in the 1930s during the race to characterize the adrenal steroids. Its first clinical use was not as a hormone replacement but as a cheap, apparently non-toxic oral steroid. Gregory Pincus and Hudson Hoagland studied it in the 1940s for stress tolerance and work performance, and by 1950 several groups were testing it in rheumatoid arthritis, including a series from the Worcester Foundation and a comparison against epinephrine and testosterone.

Those reports diverged rather than converged. Some series described partial symptomatic relief in a subset of patients; others, including a Lancet series and a New England Journal of Medicine report, found little. The effect was plainly smaller and slower than what cortisone and corticotropin had just produced, and interest moved to those agents. The 1950 work was not disproven — it was outcompeted, and then abandoned before anyone established a dose-response relationship or an adequate control design.

Two later developments revived it. Étienne-Émile Baulieu’s neurosteroid concept in the 1980s established that the brain synthesizes pregnenolone locally, reframing it as a brain-active molecule rather than a spent precursor. Then the 1994 United States supplement legislation put it on the retail market, where it was marketed for memory and for slowing aging. Since 2005 a publicly funded research program, largely at Duke, Yale and the Department of Veterans Affairs, has tested it in schizophrenia, bipolar depression, chronic pain and addiction.

Expected Benefits

High 🟩 🟩 🟩

Reduced Stress- and Cue-Provoked Craving in Substance Use Disorder ⭕️ Not Central to Health & Longevity

Supraphysiological pregnenolone blunts the craving and anxiety that stress or drug cues provoke. The proposed mechanism is restoration of neuroactive steroid tone at GABA-A receptors, depleted by chronic alcohol or cocaine use. Three randomized placebo-controlled trials support it: 30 people with cocaine use disorder, 43 with alcohol use disorder, and a later 55-person cocaine trial that also measured drug use. All three come from one research group and are pilot-sized, so replication elsewhere is still owed. It bears on addiction medicine, not on longevity.

Magnitude: 300–500 mg daily prevented the rise in stress- and cue-induced craving that placebo participants showed, and the 300 mg arm used less cocaine than placebo (p = 0.047, where p is the chance of seeing a difference this large if the treatment did nothing, and below 0.05 is the usual threshold) and than the 500 mg arm (p = 0.01); the trials report no standardized effect size (a scale-free number for how large a difference is) for craving. Sources: Milivojevic et al., 2022, Milivojevic et al., 2023, Sakmar et al., 2025.

Medium 🟩 🟩

Reduced Chronic Low Back Pain

A single, well-conducted randomized trial in 94 Iraq- and Afghanistan-era veterans found less self-reported back pain on pregnenolone than on placebo after four weeks, plus less interference of pain with work and with activity. The proposed mechanism is neurosteroid modulation of pain signaling rather than any anti-inflammatory action. Participants averaged 38 years of age and the dose escalated to 500 mg daily — five to ten times typical supplement doses. Sleep, mood, working memory and physical function did not improve. One trial, so one grade below replicated.

Magnitude: Pain diary ratings fell 0.56 points more than placebo on a 0–10 scale (p = 0.02) and recalled pain 0.70 points more (p = 0.01), roughly a 20% reduction against 6% on placebo. Source: Naylor et al., 2020.

Improved Depressive Symptoms in Bipolar Depression ⭕️ Not Central to Health & Longevity

In 80 adults in a depressed phase of bipolar disorder, twelve weeks of pregnenolone added to existing treatment improved depression ratings relative to placebo. The proposed mechanism is elevation of allopregnanolone and pregnanolone, both of which correlated inversely with anxiety improvement within the trial. The two rating instruments disagreed: the clinician scale moved, the self-report total did not, though its remission rate favored pregnenolone. A smaller trial in people with mood disorder plus a substance use history saw only non-significant trends. It bears on psychiatry, not longevity.

Magnitude: Remission in 61% on pregnenolone versus 37% on placebo (p = 0.046); clinician-rated depression improved significantly faster on pregnenolone than on placebo across the twelve weeks (p = 0.025). Sources: Brown et al., 2014, Osuji et al., 2010.

Improved Everyday Functional Capacity in Schizophrenia ⭕️ Not Central to Health & Longevity

In the largest pregnenolone trial run to date — 120 participants in Singapore, eight weeks, escalating to 500 mg daily — pregnenolone improved performance-based functional capacity, a simulated test of tasks such as communication and financial management, without improving the cognitive battery that was the co-primary endpoint. The proposed mechanism is metabolism to pregnenolone sulfate, which positively modulates NMDA receptors. The dissociation between function and cognition is unexplained. One trial, and the functional measure has not been replicated. It bears on psychiatric rehabilitation, not longevity.

Magnitude: Functional capacity composite favored pregnenolone over placebo (p = 0.03), with the communication subscale strongly favoring it (p < 0.001); no between-group difference on the cognitive composite. Source: Marx et al., 2014.

Low 🟩

Reduced Negative Symptoms of Schizophrenia ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Individual trials found moderate reductions in flattened emotion, low motivation and loss of pleasure; the largest trial and the pooled analyses did not. It bears on psychiatry, not longevity. Net reading: several positive small trials exist, but the pooled evidence does not support a reliable effect on negative symptoms.

Magnitude: Effect sizes of 0.79 and 0.57 on two negative-symptom scales in one 60-person trial, against no overall pooled effect across four trials. Sources: Ritsner et al., 2014, Heringa et al., 2015, Kashani et al., 2017.

Improved Attention and Working Memory ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Low-dose and add-on trials in recent-onset schizophrenia improved visual and sustained attention; two other trials found nothing on standardized batteries. It bears on psychiatry; no trial has tested cognition in adults without a diagnosis. Net reading: a real but narrow attentional signal that does not generalize.

Magnitude: Effect size 0.42 on a visual-attention task (p = 0.002) in 60 participants; no change in cognitive composites in two trials totalling 141 participants. Sources: Kreinin et al., 2017, Ritsner et al., 2010, Marx et al., 2009, Marx et al., 2014.

Reduced Irritability in Autism Spectrum Disorder ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

An open-label study and one placebo-controlled add-on trial both reported less irritability; the team running a later controlled trial found a two-week placebo lead-in alone cut irritability scores by 30%. It bears on autism care, not longevity. Net reading: promising in uncontrolled settings, unconfirmed once placebo is accounted for.

Magnitude: Irritability scores fell from 17.4 to 11.2 over twelve weeks open-label (p = 0.028); the controlled add-on trial favored pregnenolone (p = 0.025). Sources: Fung et al., 2014, Ayatollahi et al., 2020, McGrath et al., 2025.

Relieved Rheumatoid Arthritis Symptoms ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Mid-century series gave oral pregnenolone for rheumatoid arthritis. Some reported partial symptomatic relief in a subset of patients; Lancet and New England Journal reports found little. No modern controlled trial has retested it. It bears on joint disease, not longevity. Net reading: an unresolved historical signal, never adequately controlled.

Magnitude: Direction was inconsistent — partial relief in some series, none in others — and the mid-century reports give no standardized outcome figure. Sources: Freeman et al., 1950, Stock & McClure, 1950, Dordick et al., 1951.

Speculative 🟨

Extended Lifespan in a Model Organism

Pregnenolone lengthened the lifespan of the nematode Caenorhabditis elegans in a single invertebrate study, where removing the germline also raised the worm’s own pregnenolone. No vertebrate or human lifespan data exist.

Preserved Memory and Neuronal Plasticity with Age

Aged rats with poor spatial memory have low hippocampal pregnenolone sulfate, and restoring it rescues performance. No human trial has tested memory in healthy older adults; the basis is animal and mechanistic only.

Raised Downstream Neurosteroid Levels

Oral dosing reliably raises pregnenolone, allopregnanolone and pregnanolone in human serum, and twice-daily dosing keeps levels stable. These are unvalidated biomarkers: no trial has shown that raising them raises testosterone, estradiol or DHEA.

Blunting of Cannabis Intoxication ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Rodent work shows pregnenolone curbs cannabis’s active compound through the CB1 receptor; one slice study found no such action, and no human trial has reported results. It bears on intoxication care, not longevity. Net: unresolved.

Benefit-Modifying Factors

  • Baseline neurosteroid status: Lower pre-treatment pregnenolone, pregnenolone sulfate and allopregnanolone predicted greater cognitive improvement in the first controlled trial (correlations of −0.76 to −0.83). Those already in the upper part of the reference range have the least room to gain.

  • Sex: Change in serum pregnenolone tracked functional improvement in women but not men in the 120-person trial. Serum pregnenolone sulfate also follows different age curves in the two sexes, peaking near 30 in women and around a decade earlier in men.

  • Enzyme genotype: Variants in CYP17A1 (opens the androgen branch), HSD3B2 (converts to progesterone) and SULT2A1 (makes the sulfate) determine how a given dose is partitioned. The sulfate arm drives arousal; the progesterone arm drives calm. No genotype-stratified trial exists.

  • Pre-existing health conditions: Every positive human result comes from people with schizophrenia, bipolar depression, chronic low back pain, autism or a substance use disorder. Benefit in adults without a diagnosis is untested, and the trials give no basis for extrapolating to them.

  • Age: Whether pregnenolone falls with age is contested — a study across the menopausal transition and one in postmenopausal women found no decline, while a larger regression analysis found a fall after 30 in women. Older adults may therefore have no deficit to correct.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the available safety data are single-trial tolerability tables and uncontrolled consumer-reference reports, neither of which is the replicated clinical-endpoint evidence this level requires.

Medium 🟥 🟥

Central Nervous System Overstimulation

The most consistently reported problem is arousal where none was wanted: agitation, restlessness, confusion, tingling, disturbed sleep and irritability. The proposed mechanism is pregnenolone sulfate’s dual action — strengthening NMDA receptor signaling while weakening GABA-A receptor signaling — which shifts the brain toward excitation. The 94-person back-pain trial tabulated these at 500 mg daily. Most were mild and resolved on stopping, but the trial did not test whether the excess over placebo was significant, and consumer references list the same cluster plus headache at far lower doses.

Magnitude: Among 45 pregnenolone and 49 placebo participants: excitement or agitation 5 versus 0, confusion 2 versus 0, tingling 4 versus 1. Source: Naylor et al., 2020.

Digestive Upset

Nausea, diarrhea and loss of appetite were each reported more often on pregnenolone than on placebo in the 94-person back-pain trial at 500 mg daily. No mechanism has been established; the compound is a fat-soluble steroid given in gram-scale capsules, so a local effect on the gut lining is the likeliest explanation. All were mild and resolved on stopping, and the trial did not test whether the excess over placebo was significant.

Magnitude: Among 45 pregnenolone and 49 placebo participants: nausea 7 versus 4, diarrhea 6 versus 3, reduced appetite 7 versus 4. Source: Naylor et al., 2020.

Low 🟥

Altered Cardiovascular Response to Stress ⚠️ Conflicted

In one trial pregnenolone lowered stress-induced heart rate and blood pressure; in a companion trial in a different population it raised them. Consumer references also report palpitations, sometimes at doses as low as 5 mg. Net reading: pregnenolone measurably changes autonomic reactivity, but the direction is population-dependent and unpredictable.

Magnitude: Direction reversed between the two trials — reduced stress-induced heart rate and both blood pressures in cocaine use disorder, increased stress-induced heart rate and systolic pressure in alcohol use disorder; neither trial reports absolute millimetres of mercury or beats per minute against placebo. Sources: Milivojevic et al., 2022, Milivojevic et al., 2023.

Androgenic and Estrogenic Effects from Downstream Conversion

Because pregnenolone feeds the androgen and estrogen branches, acne, oily skin, hair loss, unwanted facial hair and menstrual irregularity are the expected effects, and consumer references report them. No controlled trial has measured sex-hormone endpoints after dosing, so the size of the conversion is unknown.

Magnitude: Not quantified in available studies. No controlled trial has measured testosterone, estradiol or clinical androgenic endpoints after pregnenolone administration; the evidence is uncontrolled clinical and consumer reporting. Source for the conversion pathway: Vallée, 2016.

Undeclared Hormones in Blended “Adrenal Support” Products

People who obtain pregnenolone inside multi-ingredient “adrenal support” formulas receive undeclared hormones. A blinded assay of twelve such products found every one contained thyroid hormone and several a synthetic glucocorticoid (an inflammation-suppressing steroid drug). Doses are small but chronic. This is indirect evidence — product chemistry, not measured harm.

Magnitude: All 12 products contained triiodothyronine; 42% contained pregnenolone, 25% budesonide, 17% androstenedione. Label-recommended daily exposure reached 1,322 ng triiodothyronine, 1,276 ng budesonide and 1,231 ng pregnenolone. Source: Akturk et al., 2018.

Speculative 🟨

Stimulation of Androgen-Receptor-Mutant Prostate Cancer Cells

At normal male blood concentrations, pregnenolone drove 7–8-fold growth of a prostate cancer line carrying a mutated androgen receptor, and grew those tumors in mice. Laboratory and animal work only.

Suppression of the Body’s Own Steroid Production

Sustained supraphysiological dosing should, by ordinary negative feedback, reduce endogenous steroid synthesis. No human trial has measured recovery of adrenal or gonadal output after stopping pregnenolone, so this rests on mechanism alone.

Lowered Seizure Threshold

Pregnenolone sulfate strengthens NMDA signaling and weakens GABA-A signaling, the combination that provokes seizures in animals. No seizure has been reported in any trial; the concern is mechanistic only.

Risk-Modifying Factors

  • Androgen receptor and 5α-reductase genotype: Androgen receptor mutations of the type found in castration-resistant prostate cancer convert pregnenolone into a growth signal in the laboratory. Reduced 5α-reductase activity shifts metabolism away from calming allopregnanolone toward the arousal-promoting sulfate.

  • Baseline biomarker levels: A prostate-specific antigen already above 4 ng/mL, a high baseline estradiol, or sex-hormone levels near the top of the reference range all raise the consequence of further hormonal input, which is why baseline measurement matters.

  • Sex: Women face the androgenic effects — acne, unwanted facial hair, menstrual change — and any risk carried by added estrogen exposure. Men carry the prostate concern. Serum pregnenolone sulfate also follows different age trajectories in the two sexes.

  • Pre-existing health conditions: Hormone-sensitive cancers, endometriosis, uterine fibroids, uncontrolled epilepsy, established arrhythmia and insomnia all amplify specific effects described above. Treatment with a CYP17A1 inhibitor makes supplementation directly counterproductive.

  • Age: Older adults carry higher background prevalence of prostate disease and atrial fibrillation, the two conditions that turn a mild effect into a serious one, and are also the group least likely to have a genuine deficit to correct.

Key Interactions & Contraindications

  • Benzodiazepines and other GABA-A sedatives (diazepam, lorazepam, zolpidem): Caution. Four weeks of low-dose pregnenolone significantly reduced diazepam sedation in a controlled crossover study, so expected sedation may fail. Mitigation: dose separation, and disclosure to anesthesia staff before procedural sedation. Meieran et al., 2004.

  • Steroidogenesis inhibitors (abiraterone, ketoconazole, aminoglutethimide, metyrapone): Absolute contraindication with abiraterone. These drugs are prescribed to starve tumors of androgen precursors; pregnenolone supplies substrate upstream of the block. Mitigation: none — no dose adjustment makes the combination safe.

  • 5α-Reductase inhibitors (finasteride, dutasteride): Caution. They block formation of calming allopregnanolone, tilting output toward the arousal-promoting sulfate. Mitigation: a low starting dose and morning-only timing, since stimulation is likelier.

  • Hormone therapies and blockers (testosterone, estradiol, tamoxifen, anastrozole): Caution. Additive or opposing hormonal load, and pregnenolone confounds interpretation of the monitoring labs. Mitigation: sex-hormone measurement at baseline and again at 8–12 weeks.

  • Corticosteroids (prednisone, hydrocortisone, dexamethasone — steroid drugs given to damp inflammation or replace adrenal output): Monitor. Both act on the adrenal axis; exogenous glucocorticoid suppresses the pituitary drive that pregnenolone otherwise feeds. Mitigation: morning cortisol monitoring; pregnenolone is not a steroid-taper agent.

  • Thyroid hormone (levothyroxine, liothyronine): Monitor. Blended adrenal-support products containing pregnenolone also contain undeclared triiodothyronine, risking unintended additive thyroid dosing. Mitigation: single-ingredient pregnenolone, with thyroid-stimulating hormone rechecked at 8–12 weeks. Akturk et al., 2018.

  • Sedating antihistamines sold without prescription (diphenhydramine, doxylamine): Caution. Pregnenolone’s arousal-promoting metabolite can offset intended sedation and worsen insomnia. Mitigation: morning-only pregnenolone timing rather than antihistamine escalation.

  • Hormone-precursor supplements (DHEA, androstenedione, topical progesterone): Caution, and these are additive by design. Stacking them multiplies androgen and estrogen load while making it impossible to attribute any lab change. Mitigation: one hormone precursor at a time.

  • Stimulant supplements (caffeine, Rhodiola rosea, tyrosine): Caution. Additive overstimulation, insomnia and palpitations, the same cluster pregnenolone produces alone. Mitigation: early dosing and a capped total stimulant load on dosing days.

  • Cannabis: Monitor. Pregnenolone acts as a signaling-specific brake on the CB1 receptor and blunts cannabis’s effects in rodents, so its effect may be weaker than expected. No human confirmation yet. Vallée et al., 2014.

Populations who should avoid Pregnenolone:

  • Anyone with active or previously treated prostate cancer at any stage, and men with a prostate-specific antigen above 4 ng/mL or a rise exceeding 0.75 ng/mL per year pending urological assessment
  • Anyone with active or previously treated breast, endometrial or ovarian cancer
  • Anyone taking abiraterone or another CYP17A1 inhibitor for prostate cancer
  • Women who are pregnant at any gestational age or breastfeeding
  • Anyone with symptomatic endometriosis or uterine fibroids causing heavy bleeding
  • Anyone with a documented arrhythmia such as atrial fibrillation or frequent ventricular ectopy (extra beats arising in the heart’s lower chambers), or taking antiarrhythmic therapy
  • Anyone with epilepsy that is not fully controlled on current medication

Risk Mitigation Strategies

  • Low starting dose with slow titration: Protocols begin at 5–10 mg, far below the 300–500 mg used in trials, holding two weeks before 5–10 mg increments. This limits overstimulation, agitation and insomnia, the most consistently reported adverse cluster.

  • Morning-only dosing, before 10 a.m.: Pregnenolone sulfate weakens GABA-A signaling and strengthens NMDA signaling, favoring wakefulness. Morning-only dosing prevents the sleep disruption and night-time restlessness that evening dosing causes.

  • Single-ingredient products only: “Adrenal support” blends, excluded under this strategy, carried undeclared thyroid hormone in 100% of products and a synthetic glucocorticoid in 25%. This removes the undeclared-hormone exposure entirely.

  • Baseline hormone panel repeated at 8–12 weeks: The panel covers pregnenolone, DHEA sulfate, testosterone, estradiol and morning cortisol. It detects androgenic or estrogenic drift before acne, hair loss or menstrual change appear.

  • Men aged 40 and over: baseline prostate-specific antigen, then annually: Laboratory work shows pregnenolone drives growth of androgen-receptor-mutant prostate cancer cells. A rise above 0.35 ng/mL in a year is a stop-and-refer threshold.

  • Weekly blood pressure and pulse during titration: Pregnenolone changes autonomic reactivity in opposite directions in different populations, and palpitations are reported. Any new irregular rhythm is a stop signal, not a dose-reduction signal.

  • A stop date fixed before starting: A defined 12-week trial against pre-specified targets bounds exposure. No human study extends beyond twelve weeks, so open-ended use exceeds the entire evidence base and accumulates unmeasured hormonal exposure.

  • Eight-hour separation from benzodiazepines: Pregnenolone measurably reduces diazepam sedation. Timing separation preserves the sedative’s effect and removes the pressure to escalate its dose.

Therapeutic Protocol

  • Standard supplement protocol: Most practitioners who use pregnenolone give 5–50 mg orally once daily, titrated by symptoms and labs. Life Extension, which sells the product, suggests 50–100 mg daily targeting a serum level of 125–175 ng/dL.

  • Research protocol, an alternative rather than a default: Trials used fixed escalation to 500 mg daily over four weeks, or 300–500 mg split twice daily. Neither approach has been compared head-to-head with low-dose supplement practice.

  • Low dose may outperform high dose: In the one trial comparing doses directly, 30 mg daily improved symptoms, attention and working memory while 200 mg daily did nothing. Ritsner et al., 2010. Dose-response is not monotonic.

  • Who popularized each approach: The low-dose approach traces to Life Extension, which sells pregnenolone, from 1996 onward; the high-dose approach to Christine Marx’s group at Duke and the Durham Veterans Affairs center, and Rajita Sinha’s group at Yale.

  • Best time of day: Morning. The arousal-promoting sulfate metabolite and the documented reduction in benzodiazepine sedation both argue against evening dosing, and the trial literature and supplement guidance agree on early administration.

  • Half-life: No formal human half-life has been published. Serial sampling over 32.5 hours showed 300–500 mg daily split into two doses produced stable elevations, with levels still strongly correlated eight hours post-dose. Gao et al., 2024.

  • Single versus split dosing: Supplement-range doses are given as a single morning dose. At 300 mg and above, trials split the dose twice daily, which is what produced the stable plasma levels described above.

  • Genetic factors in dose choice: CYP17A1, HSD3B2 and SULT2A1 variants determine how much of a dose becomes androgen precursor, progesterone or the arousal-promoting sulfate. No pharmacogenetic dosing data exist; genotype currently informs expectation, not dose.

  • Sex differences: In the largest trial, rising serum pregnenolone tracked functional improvement in women but not men. Other trials found sex did not predict response. Women may need lower doses given androgenic conversion.

  • Age considerations: Protocols for adults past 60 begin at the bottom of the range. Background prostate disease and arrhythmia prevalence rise with age, and whether pregnenolone itself declines with age is disputed, so a deficit cannot be assumed.

  • Baseline biomarkers guide dose: Lower baseline pregnenolone, pregnenolone sulfate and allopregnanolone predicted greater cognitive gain. Marx et al., 2009. Those already mid-range or higher have little rationale for supraphysiological dosing.

  • Pre-existing conditions altering response: Chronic alcohol or cocaine use depletes neuroactive steroids, which is why supraphysiological doses were chosen in those trials. Absent such depletion, the same doses have no established rationale.

Discontinuation & Cycling

  • Intended duration: Short-term. Every controlled trial ran four to twelve weeks and then stopped; no human data exist beyond twelve weeks, so indefinite use is entirely outside the evidence base.

  • Withdrawal effects: None documented. Trials stopped pregnenolone abruptly at four, eight and twelve weeks without reported rebound, mood deterioration or physical withdrawal, though none followed participants specifically to look for it.

  • Tapering: Not required by the trial evidence, which used abrupt discontinuation. After prolonged supraphysiological dosing a two-week halving step is a reasonable precaution against theoretical feedback suppression, but no study has tested it.

  • Cycling: No trial has compared continuous with intermittent dosing, so any cycling schedule is practice rather than evidence. Time-limited blocks with a formal reassessment serve the same purpose and keep total exposure measurable.

  • Reassessment rather than routine continuation: If the target symptom has not moved by twelve weeks, the evidence gives no basis for continuing. Stopping and re-measuring the baseline panel distinguishes a real effect from drift.

Sourcing and Quality

  • Regulatory status shapes the supply: The United States Anti-Doping Agency states the Food and Drug Administration regards pregnenolone as an unapproved new drug that cannot legally be compounded or included in dietary supplements, yet it is sold widely as one. USADA.

  • Single-ingredient products: Blended “adrenal support” formulas carried undeclared thyroid hormone in every one of twelve products tested and a synthetic glucocorticoid in a quarter. Akturk et al., 2018. A single-ingredient capsule removes that exposure.

  • What to look for: Third-party verification from a recognized program such as USP, NSF or Informed Choice; a batch certificate of analysis stating identity and quantity; micronized pregnenolone for absorption; an expiry date and lot number on the bottle.

  • No independent product review exists: ConsumerLab, which tests supplements against label claims, has published an answer on pregnenolone but no product review of pregnenolone brands. Buyers therefore have no independent comparison of label accuracy across brands.

  • Reputable single-ingredient brands: Life Extension (which profits from pregnenolone), Pure Encapsulations and Double Wood sell single-ingredient pregnenolone capsules and state third-party testing for identity, potency and contaminants. None has been independently verified against label claim.

  • Compounding pharmacies: Sublingual and transdermal pregnenolone are offered by compounders, but the regulator’s position above makes that route legally contested, and no trial has tested any non-oral formulation for absorption or effect in people.

  • Formulation: All human trial evidence used oral pregnenolone. Sublingual, liposomal and cream products make absorption claims that no published human pharmacokinetic study supports, so the trial doses cannot be translated to them.

Practical Considerations

  • Time to effect: Craving and anxiety effects appeared within two weeks of starting; back pain improved over four weeks at escalating doses; psychiatric symptom and cognitive changes were measured at eight to twelve weeks. Nothing acts within days.

  • Pitfall — assuming an age-related deficit: Measurement studies found no fall in pregnenolone across the menopausal transition or with age in postmenopausal women. The premise that supplementation corrects an age-related decline is contested, not established.

  • Pitfall — assuming more is better: The only dose-comparison trial found 30 mg daily effective and 200 mg daily inert. Escalating toward research doses without a reason risks the overstimulation cluster while possibly moving away from the effective range.

  • Pitfall — expecting testosterone or estrogen to rise: Dosing reliably raises pregnenolone and its immediate neuroactive metabolites. No trial has shown it raises testosterone, estradiol or DHEA, which is the effect most supplement marketing implies.

  • Pitfall — evening dosing and blended products: Taking pregnenolone late causes the insomnia most commonly reported, and buying it inside an adrenal-support blend adds undeclared thyroid and glucocorticoid hormone.

  • Regulatory status: Sold without prescription in the United States despite the regulator’s unapproved-new-drug position; not prohibited under the World Anti-Doping Agency list, though that list is revised annually; not marketed as a retail supplement in the European Union, United Kingdom, Canada or Australia.

  • Cost and access: Inexpensive and easy to obtain in the United States — typically under 20 US dollars a month at 50 mg daily. Access is the constraint outside the United States, not price.

Interaction with Foundational Habits

  • Sleep: Direct and potentially disruptive. Pregnenolone sulfate weakens GABA-A signaling and strengthens NMDA signaling, and four weeks of dosing measurably reduced benzodiazepine sedation in people. Rodent work showing increased deep-sleep activity points the other way, so the net human direction is unsettled; dose before 10 a.m. and stop if sleep onset lengthens.

  • Nutrition: Indirect. Pregnenolone is synthesized from cholesterol, so very low dietary fat or aggressive cholesterol-lowering plausibly limits substrate, though no human study has tested this. Being fat-soluble, it is better absorbed with a meal containing fat. No nutrient depletion has been documented.

  • Exercise: None established. No trial has examined pregnenolone with training, and no effect on strength, endurance or recovery has been measured. Rodent work shows voluntary running itself changes neuroactive steroid levels, which raises the possibility of overlap but supplies no practical timing guidance around workouts.

  • Stress management: Direct and potentially potentiating. In trials, pregnenolone normalized cortisol and corticotropin responses and reduced stress-provoked craving and anxiety — the same axis that breathing practice, meditation and sleep regularity target. The two are complementary; the behavioural work also remains the better-evidenced half of the pair.

Monitoring Protocol & Defining Success

The baseline panel taken before the first dose comprises serum pregnenolone drawn in the morning, DHEA sulfate, total and free testosterone, estradiol, progesterone, morning cortisol, sex hormone-binding globulin, and — for men aged 40 and over — prostate-specific antigen. Resting blood pressure and pulse are recorded alongside it, together with the specific symptom the trial is meant to change, scored numerically so that a change is detectable.

Ongoing monitoring repeats the full hormone panel at 8–12 weeks, then every 6 months while use continues, with blood pressure and pulse weekly during titration and monthly thereafter, and prostate-specific antigen annually in men. Success is a measurable improvement in the pre-specified symptom score with no drift in androgen or estrogen markers; absence of that improvement at twelve weeks is a stop signal rather than an escalation signal.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum pregnenolone No independently validated target exists; track change from the individual’s own baseline. Life Extension, which sells pregnenolone, promotes 125–175 ng/dL Confirms the dose is absorbed and quantifies the size of the change Conventional adult reference range runs roughly 10–230 ng/dL and is highly laboratory-dependent. Drawn in the morning; fasting not required
DHEA sulfate Men 350–500 µg/dL; women 200–300 µg/dL Shows whether the androgen branch downstream of pregnenolone is being pushed DHEA sulfate is dehydroepiandrosterone sulfate, the storage form of the main adrenal androgen precursor. Conventional ranges fall steeply with age, so an age-adjusted “normal” can sit well below the functional target
Total and free testosterone Men 600–900 ng/dL total; women 30–70 ng/dL total Detects androgenic conversion before acne or hair loss appear Conventional reference for men runs roughly 264–916 ng/dL, so the functional target sits in its upper half. Morning draw before 10 a.m., paired with sex hormone-binding globulin, which determines how much is biologically available
Estradiol Men 20–30 pg/mL; premenopausal women interpreted against cycle day; postmenopausal women under 30 pg/mL Detects estrogenic conversion, the relevant concern in hormone-sensitive conditions Estradiol is the principal form of estrogen. A sensitive assay is needed in men and postmenopausal women, as standard assays are unreliable at low levels
Progesterone Women, mid-luteal 10–20 ng/mL; men under 1.0 ng/mL Pregnenolone converts directly to progesterone, so this is the closest downstream marker In cycling women, timing decides the result: drawn 7 days after ovulation, paired with estradiol
Morning cortisol 10–18 µg/dL drawn between 7 and 9 a.m. Pregnenolone supplies substrate for cortisol; confirms the adrenal axis is not being driven Conventional reference extends to about 23 µg/dL, wider than the functional target. Drawn at a consistent time, since delay past 9 a.m. lowers the result artefactually
Sex hormone-binding globulin 20–60 nmol/L in both sexes Determines the free, active fraction of any hormone change seen above Sex hormone-binding globulin is the carrier protein for sex steroids. Rises with thyroid excess, which matters when blended products carry undeclared thyroid hormone
Prostate-specific antigen (men 40 and over) Under 1.0 ng/mL before age 60, under 1.5 ng/mL thereafter; annual rise under 0.35 ng/mL Laboratory work shows pregnenolone drives growth of androgen-receptor-mutant prostate cancer cells Prostate-specific antigen is a protein made by the prostate. Conventional practice treats 4.0 ng/mL as the referral threshold, well above the functional target. Cycling, ejaculation and prostate examination in the 48 hours before the draw all raise it
Thyroid-stimulating hormone with free thyroxine Thyroid-stimulating hormone 0.5–2.0 mIU/L; free thyroxine in the upper half of the laboratory range Blended adrenal-support products carry undeclared triiodothyronine Thyroid-stimulating hormone is the pituitary signal to the thyroid; free thyroxine is the main circulating thyroid hormone. The conventional reference range runs roughly 0.4–4.5 mIU/L, far wider than the functional target. Only needed if a blended product was used
Resting blood pressure and pulse Under 120/80 mmHg; resting pulse 50–70 beats per minute Palpitations are reported, and autonomic stress reactivity changes measurably on pregnenolone Measured seated after 5 minutes’ rest, same arm each time. Any new irregular rhythm is a stop signal, not a dose-reduction signal

Qualitative markers worth tracking alongside the labs:

  • Time to fall asleep and number of night wakings
  • Morning energy on waking, scored 1–10
  • Irritability, agitation and restlessness
  • Mental clarity and ability to sustain attention through a working session
  • Libido
  • Skin oiliness and new acne
  • Scalp hair shedding, and facial hair growth in women
  • Menstrual cycle length and flow
  • The specific pain or symptom score chosen at baseline

Emerging Research

  • Post-traumatic stress disorder in veterans: A Department of Veterans Affairs phase 2 randomized trial of neurosteroids for post-traumatic stress disorder enrolled 97 participants and completed in July 2025, with change in a clinician-administered symptom scale as the primary endpoint. NCT03799562. Results were posted to the registry in August 2026 but not yet published.

  • Alcohol use disorder, the largest trial to date: Yale is running a 150-participant phase 2 trial of pregnenolone for alcohol use disorder, with percentage of participants having no heavy drinking days and pregnenolone safety as co-primary endpoints, completing in 2028. NCT05781009.

  • Cannabis intoxication, the first human test of the CB1 mechanism: Johns Hopkins is recruiting 20 participants for a phase 2 trial measuring whether pregnenolone blunts the subjective, movement-related and psychosis-like effects of cannabis. NCT07216690. This directly tests the rodent finding.

  • Chronic low back pain, the replication that matters: A 108-participant adaptive phase 2 trial in veterans is scheduled to start, using the same pain rating scale as the positive 2020 trial. NCT05935761. A null result here would undercut the strongest pain claim.

  • Evidence that could weaken the case — placebo response: The team running a 40-participant phase 2 autism trial (NCT02627508) published an analysis attributing much of the observed change to placebo response. McGrath et al., 2025.

  • Evidence that could weaken the case — bias correction: A 2026 meta-analysis of 74 trials found pregnenolone’s already small symptom effect shrank further once selective publication and English-only study selection were accounted for. Li et al., 2026. Larger, registered trials are needed to settle it.

  • Unresolved question — does it actually fall with age: Studies disagree. Meldrum et al., 1981 found no age-related change in postmenopausal women, while Meloun et al., 2009 found a fall after age 30 in women. The longevity rationale depends on this.

  • Unresolved question — the prostate signal: Grigoryev et al., 2000 showed pregnenolone drives androgen-receptor-mutant prostate cancer growth in cells and mice. Cohort work on circulating progestogens and colorectal cancer found no association. Michels et al., 2021.

  • Next-generation compounds: The most promising direction is pregnenolone-like molecules engineered to resist conversion into other steroids, retaining the brain activity without the hormonal load. Vallée, 2016. None has reached human testing.

  • Structural note on who funds this work: Pregnenolone is unpatentable and cheap, and every trial above is funded by government or academic sponsors rather than industry. Cost-conscious payers have no incentive to suppress it; the missing incentive is commercial sponsorship for the large trials that would settle the question.

Conclusion

Pregnenolone is the hormone at the head of the steroid pathway, and it is also active in the brain in its own right, shifting the balance toward alertness. Those two facts have kept it in circulation for eighty years, first as a discarded arthritis treatment and now as a retail supplement.

The human evidence is narrower than the marketing. The strongest findings — less craving in addiction, less chronic back pain, better everyday functioning in psychosis — come from small trials in people with specific diagnoses, at doses five to ten times what supplement labels suggest. Where the trials have been added together, the combined result on mental-health symptoms mostly disappears. No study has tested pregnenolone in adults without a diagnosis who are seeking more healthy years, no study has run past twelve weeks, and the central marketing premise — that levels fall with age and need replacing — is contested by the measurement studies themselves. Nothing shows it raises testosterone or estrogen.

The harms are modest but real: overstimulation and sleep disruption, unpredictable changes in cardiovascular stress responses, and expected hormonal effects that no trial has actually measured. Laboratory work linking pregnenolone to growth of hormone-driven prostate cancer cells remains unresolved in people.

The evidence base is publicly funded rather than industry-sponsored, which removes one common bias but also explains why trials stayed small. The one consumer overview that recommends it, Life Extension, sells the product.

Top - Benefits - Risks - Protocol